SK Capital Partners supports Swixx BioPharma’s global expansion

US-based private investment company SK Capital Partners’ affiliate has agreed to invest in Swixx BioPharma to support the latter’s next stage of growth and international expansion. The investment values Swixx at more than €1.5bn ($1.76bn). Swixx operates as a commercialisation platform for pharma companies, focusing on markets where those companies have chosen not to enter or have exited. The company’s mission is to provide access to essential medications in hard-to-reach and underserved regions. Swix ...